跳转至内容
Merck
CN
  • Mechanistic effects of amino acids and glucose in a novel glutaric aciduria type 1 cell model.

Mechanistic effects of amino acids and glucose in a novel glutaric aciduria type 1 cell model.

PloS one (2014-10-22)
Xi Fu, Hongjie Gao, Fengyan Tian, Jinzhi Gao, Liping Lou, Yan Liang, Qin Ning, Xiaoping Luo
摘要

Acute neurological crises involving striatal degeneration induced by a deficiency of glutaryl-CoA dehydrogenase (GCDH) and the accumulation of glutaric (GA) and 3-hydroxyglutaric acid (3-OHGA) are considered to be the most striking features of glutaric aciduria type I (GA1). In the present study, we investigated the mechanisms of apoptosis and energy metabolism impairment in our novel GA1 neuronal model. We also explored the effects of appropriate amounts of amino acids (2 mM arginine, 2 mM homoarginine, 0.45 g/L tyrosine and 10 mM leucine) and 2 g/L glucose on these cells. Our results revealed that the novel GA1 neuronal model effectively simulates the hypermetabolic state of GA1. We found that leucine, tyrosine, arginine, homoarginine or glucose treatment of the GA1 model cells reduced the gene expression of caspase-3, caspase-8, caspase-9, bax, fos, and jun and restored the intracellular NADH and ATP levels. Tyrosine, arginine or homoarginine treatment in particular showed anti-apoptotic effects; increased α-ketoglutarate dehydrogenase complex (OGDC), fumarase (FH), and citrate synthase (CS) expression; and relieved the observed impairment in energy metabolism. To the best of our knowledge, this study is the first to investigate the protective mechanisms of amino acids and glucose in GA1 at the cellular level from the point of view of apoptosis and energy metabolism. Our data support the results of previous studies, indicating that supplementation of arginine and homoarginine as a dietary control strategy can have a therapeutic effect on GA1. All of these findings facilitate the understanding of cell apoptosis and energy metabolism impairment in GA1 and reveal new therapeutic perspectives for this disease.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
β-烟酰胺腺嘌呤二核苷酸 水合物, ≥96.5% (HPLC), ≥96.5% (spectrophotometric assay), from yeast
Sigma-Aldrich
β-烟酰胺腺嘌呤二核苷酸 水合物, ≥95% (HPLC)
Sigma-Aldrich
β-烟酰胺腺嘌呤二核苷酸 水合物, ≥99%
Sigma-Aldrich
β-烟酰胺腺嘌呤二核苷酸 水合物, suitable for cell culture, ≥96.5% (HPLC), ≥96.5% (spectrophotometric assay), from yeast
Sigma-Aldrich
β-烟酰胺腺嘌呤二核苷酸 水合物, Grade AA-1
Sigma-Aldrich
β-烟酰胺腺嘌呤二核苷酸, pkg of 10 mg (per vial)
Sigma-Aldrich
β-烟酰胺腺嘌呤二核苷酸 水合物, ≥98%, BioUltra, from yeast
Sigma-Aldrich
β-烟酰胺腺嘌呤二核苷酸, pkg of 50 mg (per vial)
Sigma-Aldrich
二喹啉甲酸 二钠盐 水合物, ≥98% (HPLC)
精氨酸, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
β-烟酰胺腺嘌呤二核苷酸, pkg of 20 mg (per vial)
Sigma-Aldrich
β-烟酰胺腺嘌呤二核苷酸 水合物, purified by column chromatography, ≥99%
Sigma-Aldrich
β-烟酰胺腺嘌呤二核苷酸 锂盐 来源于酿酒酵母, ≥95%
亮氨酸, European Pharmacopoeia (EP) Reference Standard
酪氨酸, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
DL-亮氨酸, ≥99% (HPLC)
Sigma-Aldrich
DL-酪氨酸, 99%
Sigma-Aldrich
二喹啉甲酸 二钠盐 水合物, Vetec, reagent grade, 98%
Sigma-Aldrich
β-烟酰胺腺嘌呤二核苷酸 水合物, Vetec, reagent grade, ≥96.5%